

## The Protective Effects of Nigella Sativa Seed Oil against CCl<sub>4</sub>-Induced Hepatic Injury in Wistar Rats

Zain Khan Jadoon\*, Humaira Ansari & Sumera Afzal

Ziauddin College of Physical Therapy, 74600, Karachi, Pakistan.

**Abstract:** Carbon tetrachloride (CCl<sub>4</sub>) is a well-established hepatotoxic agent used to induce oxidative liver injury in animal models. Nigella sativa oil (NSO) possesses antioxidant, anti-inflammatory, and hepatoprotective properties attributed primarily to thymoquinone. To evaluate the protective effects of Nigella sativa oil on biochemical and physiological parameters in Wistar rats exposed to chronic CCl<sub>4</sub>-induced hepatotoxicity. Twenty-four Wistar rats (n=6 per group) were allocated into four groups: Normal, CCl<sub>4</sub>-treated, CCl<sub>4</sub>+N. sativa oil (NSO), and NSO-only. CCl<sub>4</sub> (0.8mL/kg, s.c.) was administered twice per week for eight weeks in CCl<sub>4</sub>-treated and CCl<sub>4</sub>+N. sativa oil (NSO) treated groups. NSO (1 mL/kg/day, oral gavage) was administered for eight weeks in CCl<sub>4</sub>+N. sativa oil (NSO), and NSO-only groups. During the study period, body weights of all groups were recorded on weekly basis and after 8<sup>th</sup> week rats were slaughtered to obtain blood samples for biochemical estimations. Serum was separated to evaluate AST, ALT, ALP and bilirubin levels. Statistical analysis was done by calculating mean± SD. Results showed that CCl<sub>4</sub> administration in rats caused marked elevation in serum AST, ALT, ALP, and bilirubin levels which is indicative of liver toxicity. The serum biomarkers were reduced in CCl<sub>4</sub>+NSO group suggesting it ameliorative role against CCl<sub>4</sub> induced hepatic damage. Control and NSO treated groups showed almost similar levels of the serum parameters. It is concluded that the toxic effects of CCl<sub>4</sub> are opposed by NSO suggesting its hepatoprotective potential thus can be used as a natural remedy for cure and prevention.

**Keywords:** NSO, liver, toxicity, rat.

Received: 1-12-2024

Accepted: 1-3-2025

DOI: 10.46568/bios.v6i1-2.232

**\*Correspondence:** Zain Khan Jadoon, Ziauddin College of Physical Therapy, Karachi, 74600, Pakistan. Tel: +923333573080. Email: zain.jadoon@zu.edu.pk .

### Introduction

Liver is a natural detoxification center in our body that aims to transform and facilitates removal of metabolic wastes. But in turn it may become harmed by the toxic substances produced during metabolic transformations. CCl<sub>4</sub> is an important chemical used to create oxidative stress and eventual hepatic tissue damage in experimental animals [1]. Chronic CCl<sub>4</sub> exposure disrupts liver enzyme homeostasis and alters metabolic markers, which serve as clinical indicators of hepatic dysfunction [2].

Nigella sativa has a long history of usage as a medicinal plant and belongs to family Ranunculaceae. Nigella sativa oil (NSO) is thought to provide some protection against liver injury (hepatoprotection) from chemical agents (toxins) such as carbon tetrachloride (CCl<sub>4</sub>). The mechanisms through which NSO provides hepatoprotection are thought to be through the suppression of the production of free radicals, which are harmful molecules that can cause cell death (apoptosis) and cellular damage (lipid peroxidation), as well as through the inhibition of pro-inflammatory cytokines, which are molecules that promote inflammation [3,4].



Several *in vitro* studies have suggested that NSO has the ability to inhibit oxidative stress and inflammation produced by CCl<sub>4</sub>. However, there is limited data available regarding the use of NSO as a potential therapeutic for the prevention of CCl<sub>4</sub>-induced liver damage *in vivo* [5].

Therefore, the primary purpose of this study was to investigate whether or not NSO provides any form of protection against liver damage caused by CCl<sub>4</sub> *in vivo*. Specifically, the study examined if administration of NSO would prevent changes in serum biochemical markers associated with liver damage (such as increased liver enzymes), changes in body weight, and histopathological changes seen in the livers of rats that received CCl<sub>4</sub> compared to control rats that did not receive CCl<sub>4</sub>.

## Method

### Experimental Animals

Age and body weight matched male Wistar rats were selected and purchased for this study. All procedures were in accordance with the international guidelines for animal care and rights. The rats were acclimatized for 7 days prior to any treatment and had free access to standard diet and water. Twenty-four Wistar rats were randomly assigned to one of four different treatment groups (n=6): a control group, a CCl<sub>4</sub> treatment group, a CCl<sub>4</sub> treatment group plus NSO treatment group, and an NSO-only treatment group. Each group had six rats.

### Study Duration and Treatment

All rats were housed in the same animal room and fed the same diet. All treatments began when the rats were 24 weeks old. The rats in the control and CCl<sub>4</sub> treatment groups were weighed once a week for the first 8 weeks. The rats in the CCl<sub>4</sub> treatment group received 0.8 mL/kg of CCl<sub>4</sub> subcutaneously (under the skin) two times a week. The rats in the CCl<sub>4</sub> treatment group plus NSO treatment group received 0.8 mL/kg of CCl<sub>4</sub> subcutaneously two times a week and 1 mL/kg of NSO orally once a day for 8 weeks. The rats in the NSO-only treatment group received 1 mL/kg of NSO orally once a day for 8 weeks.

### Blood Collection and Biochemical Measurements

One week after the last injection of CCl<sub>4</sub> (or one week after the last administration of NSO), all rats were euthanized and blood samples were collected and placed in tubes containing EDTA to measure serum biochemical markers of liver damage, specifically AST (aspartate aminotransferase), ALT (alanine aminotransferase), ALP (alkaline phosphatase), and bilirubin [6,7].

### Statistical Analysis

All biochemical measurements were expressed as Mean  $\pm$  SD.

### Results and Discussion

The rats receiving CCl<sub>4</sub> lost approximately 30% of their initial body weight at 8 weeks. The rats receiving both CCl<sub>4</sub> and NSO gained back some of the weight they lost and regained almost all of their lost weight by the end of the 8-week period. During the whole study period the body weights of rats in control and NSO treated groups did not show major variations in their body weights which is indicative of no toxicity created by NSO (Table 1).

The rats treated in control and NSO groups did not show any signs of toxicity as indicated by similar levels of serum indicators of liver injury i.e. AST, ALT, ALP & bilirubin. On the other hand rats in CCl<sub>4</sub> treated groups exhibited enhanced levels of these liver damage indicators whereas rats in CCl<sub>4</sub>+NSO treated groups showed reversal of liver toxicity as their levels of AST, ALT, ALP & bilirubin were declined as compared with CCl<sub>4</sub> treated groups (Table 2).



**Table 1: Body Weight Changes in Control, CCl<sub>4</sub> treated, CCl<sub>4</sub>+NSO treated and NSO treated rats.**

GROUP	WEEK							
	1	2	3	4	5	6	7	8
Control	135±4.4	170.8±20.7	153.8±9.5	178 ±7.7	159.2±5.9	149.4±6.07	136±6.5	134.2±8.7
CCL4 treated	147.33 ±7.76	138.33±6.76	143.33±9.95	178 ±16.85	132.33±10.1	132.66±9.7	88 ±8.7	129.33±9.76
CCL4+NSO	141.33±6.7	140±4.5	139±5.3	139.5±6.8	140.3±3.2	140.6±8.5	141±7.8	142±4.3
NSO ONLY	145±6.5	145±6.66	144±7.5	1444.34±5.6	144.1±6.4	144±4.3	144.2±8.7	144.3±7.5

Data is presented as Mean ± SD

**Table 2: Serum Enzymes and Bilirubin Level in Control, CCl<sub>4</sub> treated, CCl<sub>4</sub>+NSO treated and NSO treated rats.**

SERUM MARKERS	Normal	CCL4 treated	CCL4+NSO	NSO
AST (IU/L)	8.56 ±0.11	10.5 ±0.55	17.85 ±2.192	14.6± 2.497
ALT (IU/L)	25.152 ±1.72	23.89 ±1.11	6.88±2.941	13.12±4.16
ALP (IU/L)	461.118 ±167.85	1391.61 ±1155.18	139.38± 25.370	248.7 ± 21.582
BILIRUBIN (mg/dl)	0.41 ±0.0432	0.56 ±0.024	0.504±0.2545	0.5328± 0.3792

Data is presented as Mean ± SD

The findings of this study shows that *Nigella sativa* seed oil has anti-inflammatory properties probably because of presence of antioxidants and thymoquinone and has potential to revert oxidative stress induced hepatic damage in rats and could be adopted as natural remedy to prevent and cure hepatic ailments [8]. Our results are in accordance with other studies [9, 10].

### Conclusion

Liver being detoxification center is susceptible to damage produced by chemicals during their metabolic transformation. *Nigella Sativa* seed oil consumption resulted in reversal of liver toxicity created by CCl<sub>4</sub> in rats therefore could be a choice of treatment for hepatotoxicity caused by xenobiotics.

### ETHICS APPROVAL AND CONSENT TO PARTICIPATE

Not applicable.

### HUMAN AND ANIMAL RIGHTS

No animals were used in this study. The study on humans was conducted in accordance with the ethical rules of the Helsinki Declaration and Good Clinical Practice.

### CONSENT FOR PUBLICATION

Not applicable.

### AVAILABILITY OF DATA AND MATERIALS

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

### FUNDING

The King Fahd University of Petroleum and Minerals funded this project.



**CONFLICT OF INTEREST**

The authors declare no conflict of interest, financial or otherwise.

**ACKNOWLEDGEMENTS**

None

**References**

1. Bibi S, Naz L. The therapeutic potential of *Nelumbo nucifera* against oxidative damage induced by carbon tetrachloride in rats. *Int J Endorsing Health Sci Res.* 2022;10(2):213–219.
2. Memon AA, Naz L. The hepatoprotective potentials of *Olea europaea* L. leaves against carbon tetrachloride-induced hepatic injury in rats. *J Pak Med Assoc.* 2024;74(Suppl 2):S63–S67. doi:10.47391/JPMA-DUHS-S13.
3. Sharma PC, Yelne MB, Dennis TJ, Joshi A. Database on medicinal plants used in Ayurveda. Vol. 3. New Delhi: Central Council for Research in Ayurveda and Siddha; 2005. p. 130–131.
4. Goreja WG. Black seed: nature's miracle remedy. Basel: Karger Publishers; 2003.
5. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of *Nigella sativa*: a miracle herb. *Asian Pac J Trop Biomed.* 2013;3(5):337–352. doi:10.1016/S2221-1691(13)60075-1.
6. Frankel S. A colorimetric method for the determination of serum glutamic oxaloacetic and glutamic pyruvic transaminases. *Am J Clin Pathol.* 1957;28(1):56–63.
7. Tietz NW, Burtis CA, Duncan P, Ervin K, Petittclerc CJ, Rinker AD, et al. A reference method for measurement of alkaline phosphatase activity in human serum. *Clin Chem.* 1983;29(5):751–761.
8. Nili-Ahmadabadi A, Alibolandi P, Ranjbar A, Mousavi L, Nili-Ahmadabadi H, Larki-Harchegani A, et al. Thymoquinone attenuates hepatotoxicity and oxidative damage caused by diazinon: an in vivo study. *Res Pharm Sci.* 2018;13(6):500–508. doi:10.4103/1735-5362.245962.
9. Mollazadeh H, Hosseinzadeh H. The protective effect of *Nigella sativa* against liver injury: a review. *Iran J Basic Med Sci.* 2014;17(12):958–966.
10. Krishnan N, Muthukrishnan S. Effect of *Nigella sativa* seed extract on carbon tetrachloride-induced hepatotoxicity in rats. *Journal of Acute Medicine.* 2012 Dec 1;2(4):107-13.

